Daniel Araujo, MD

An analysis found that postprogression access to effective therapy was associated with smaller OS benefits in targeted therapy trials but not in immunotherapy trials.

A cross-sectional analysis of 52 first-line trials found post-progression access to effective therapy correlated with OS benefit in targeted therapy but not checkpoint blockade.